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Background: The transcription factor nuclear factor-κB (NF-κB) has been implicated in gastric cancer metastasis, but
the underlying molecular mechanisms remain unclear. We investigated the role of the interaction between NF-κB and
signal transducers and activators of transcription 3 (STAT3) in controlling metastatic potential of gastric cancer cells.
Methods: Immunohistochemistry for NF-κB p65 (RelA), phospho-Tyr705-STAT3 (pSTAT3), or matrix metalloproteinase 9
(MMP9) was performed on tissue array slides containing 255 gastric carcinoma specimens. NF-κB inhibition in SNU-638
and MKN1 gastric cancer cell lines were performed by transduction with a retroviral vector containing NF-κB repressor
mutant of IκBα, and STAT3 was silenced by RNA interference. We also did luciferase reporter assay, double
immunofluorescence staining and immunoblotting. Cell migration and invasion were determined by wound-healing
assay and invasion assay, respectively.
Results: NF-κB and STAT3 were constitutively activated and were positively correlated (P = 0.038) in gastric cancer
tissue specimens. In cell culture experiments, NF-κB inhibition reduced STAT3 expression and activation, whereas STAT3
silencing did not affect NF-κB activation. Moreover, both NF-κB inhibition and STAT3 silencing decreased gastric cancer
cell migration and invasion in a synergistic manner. In addition, both NF-κB activation and STAT3 activation were
positively correlated with MMP9 in gastric cancer tissues (P = 0.001 and P = 0.022, respectively), decreased E-cadherin
expression and increased Snail and MMP9 expressions in cultured cells.
Conclusion: NF-κB and STAT3 are positively associated and synergistically contribute to the metastatic potential of
gastric cancer cells. Thus, dual use of NF-κB and STAT3 inhibitors may enhance the efficacy of the anti-metastatic
treatment of gastric cancer.Background
Metastasis is the major obstacle in the treatment of malig-
nant cancer and it accounts for more than 90% of cancer-
related mortality [1]. Since gastric cancer is the second
most lethal cancer worldwide [2], the underlying molecu-
lar mechanisms responsible for gastric cancer metastasis
need to be elucidated.* Correspondence: dslanat@snu.ac.kr
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reproduction in any medium, provided the orNuclear factor-κB (NF-κB) is a family of signal-responsive
transcription factors that includes RelA/p65, RelB, c-Rel,
NF-κB1/p50 and NF-κB2/p52 [3]. NF-κB exists in an in-
active form in the cytoplasm because of its interaction
with the inhibitory protein, IκBα [4]. After activation of
IκB kinases (IKKs), IκBs become phosphorylated, ubi-
quitinated and degradaded by proteasomes, which allows
NF-κB to translocate to the nucleus, where it can activate
or repress target genes [5]. With respect to gastric cancer,
NF-κB is one of the most well-studied transcription fac-
tors, and is known to be activated by various factors,
including cytokines [6-8], growth factors [9], Toll-liketd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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microbial recognition [11,12]. NF-κB activation has been
frequently observed in both gastric cancer cells [13-16] and
tumor-infiltrating lymphocytes [17]. In addition, down-
regulation of NF-κB has been shown to suppress cell
migration and invasion in gastric cancer cells in vitro
[16,18]. Thus, modulation of the NF-κB pathway might
be a promising therapeutic target for gastric cancer metas-
tasis. However, the downstream mediators of NF-κB-
induced metastasis in gastric cancer cells remain unclear.
Signal transducers and activators of transcription 3
(STAT3) belongs to the STAT family of signal-responsive
transcription factors [19]. The inactive form of STAT3
in the cytoplasm of non-stimulated cells is activated by
cytokines, growth factors and oncogenic proteins through
sequential phosphorylation of tyrosine 705 and serine 727
[20]. Like NF-κB, constitutive activation of STAT3 has
been shown to contribute to the progression of gastric can-
cer, including proliferation, apoptosis, angiogenesis and
metastasis [21-23]. However, STAT3 showed differential
roles in gastric cancer cell metastasis depending on the
upstream regulator of STAT3 activation [21].
Previously, NF-κB activation in human cancers has been
reported to be positively or negatively correlated with
STAT3 activation in the control of tumorigenesis [24],
tumor growth [3,24,25] and angiogenesis [26]. STAT3
activation increased NF-κB activation and tumor growth
derived from cervical cancer cells or glioblastoma cells
[25]. STAT3 also maintains NF-κB activation and reten-
tion in the nucleus in melanoma cells and prostate cancer
cells [27]. In addition, NF-κB activation increased STAT3
activation through up-regulation of interleukin-6 (IL-6)
in melanoma cells [26]. On the other hand, a positive
crosstalk between NF-κB and STAT3 was found in B
cell lymphoma, which increased cell proliferation and
decreased apoptosis [3]. On the contrary, an inverse re-
lationship between NF-κB and STAT3 was also shown
in human hepatocellular carcinoma cells, in which IKKβ
deletion increased STAT3 activation, tumorigenesis and
tumor growth [24]. Thus, these findings indicate that
the association between NF-κB and STAT3 could be dif-
ferent according to the cancer cell type investigated
and, thus, interaction of these two molecules in terms of
cancer cell metastasis in each cancer type needs to be
elucidated.
Since the relationship between NF-κB and STAT3 path-
ways in gastric cancer has not been described previously,
the present study performed a large scale immunohisto-
chemical analysis to investigate the correlation between
NF-κB p65 (RelA) and phospho-Tyr705-STAT3 (pSTAT3)
or matrix metalloproteinase 9 (MMP9) in 255 surgically
excised human gastric carcinoma tissues. In addition, we
inhibited NF-κB in gastric cancer cells by transduction
with a retroviral vector containing supersuppressive mutantform of IκBα (IκBαM) and silenced STAT3 by transfection
of STAT3 small interfering RNA (siRNA). Then, we evalu-
ated the effect of NF-κB and STAT3, alone or in combin-
ation, on the gastric cancer cell migration and invasion
in vitro.
Methods
Patients and tissue array methods
A total of 255 surgically resected human gastric cancer
specimens were obtained from the Department of Path-
ology, Seoul National University College of Medicine
from January 1st to June 30th, 1995 and six paraffin
array blocks were prepared by Superbiochips Laborator-
ies (Seoul, Korea), as previously described [28]. Briefly,
core tissue biopsies (2 mm in diameter) were taken from
individual paraffin-embedded gastric tumors (donor
blocks) and arranged in a new recipient paraffin block
(tissue array block) using a trephine apparatus. The
staining results of the different intratumoral areas of
gastric carcinomas in these tissue array blocks showed
an excellent agreement. A core was chosen from each
case for analysis. We defined an adequate case as a
tumor occupying more than 10% of the core area. Each
block contained internal controls consisting of non-
neoplastic gastric mucosa from body, antrum and other
areas showing intestinal metaplasia. Sections of 4 μm
thickness were cut from each tissue array block, deparaf-
finized, and rehydrated. This protocol was reviewed and
approved by the Institutional Review Board of Seoul Na-
tional University (Approval No. C-1006-035-320).
Immunohistochemistry
Immunohistochemical staining was performed as described
previously using a streptavidin peroxidase procedure (avidin-
biotin complex method) after antigen retrieval using an
autoclave [29]. The primary antibodies used were anti-
NF-κB/RelA (1:50, Santa Cruz Biotechnology, Santa Cruz,
CA, USA), anti-phospho-Tyr705-STAT3 (1:50, Cell Signal-
ing Technology, Beverly, MA, USA), anti-MMP9 (1:150,
Neomarkers, Fremont, CA, USA). Immunostaining results
were considered to be positive if ≥ 10% (for nuclear NF-
κB/RelA and cytoplasmic MMP9) or ≥ 5% (for nuclear
pSTAT3) of the neoplastic cells were stained.
Cell culture
SNU-638 and MKN1, which are well characterized human
gastric cancer cell lines [30-32], were purchased from the
Korean Cell Line Bank (Seoul, Korea). Cells were cultured
in RPMI1640 (Life Technologies, Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (FBS), 2 mg/mL
sodium bicarbonate, 100 U/mL penicillin, and 100 μg/mL
streptomycin (Life Technologies) at 37°C in a humidified
95% air and 5% CO2 atmosphere.
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supersuppressor
The control retroviral vector MFG.EGFP.IRES.puro has
been previously described [33]. MFG.EGFP.IRES.puro and
the retroviral vector MFG.IκBα.IRES.puro, which encodes
a supersuppressive mutant form of IκBαM, were generated
and infected into gastric cancer cells, as described previ-
ously [34]. Pooled puromycin-resistant cells were used for
further analysis.
STAT3 siRNA transfection
STAT3 siRNA and scrambled siRNA (control) were pur-
chased from Santa Cruz Biotechnology. STAT3 siRNA or
control siRNA was then transfected into gastric cancer cells
using LipofectAMINE Plus (Life Technologies) according
to the manufacturer’s instructions.
Preparation of nuclear and cytoplasmic extracts
Cells were scraped and lysed in cold lysis buffer A
[10 mM Tris (pH 8.0), 60 mM NaCl, 1 mM EDTA, 1 mM
DTT, 0.1% Nonidet P-40 (NP-40), 1 mM phenylmethylsul-
fonyl fluoride], incubated on ice for 10 min, centrifuged,
and the cytoplasmic extracts obtained were transferred to
fresh tubes. For nuclear extracts, the pelleted nuclei were
washed in 1 mL buffer A without NP-40 and resuspended
in 50 μL cold lysis buffer B [200 mM HEPES (pH 7.9),
0.75 mM spermidine, 0.15 mM spermine, 0.2 mM EDTA,
2 mM EGTA, 2 mM DTT, 20% glycerol, 1 mM phenyl-
methylsulfonyl fluoride, 0.4 M NaCl]. They were then
extracted on ice for 10 min with occasional vortexing. The
lysate was centrifuged at 170 g at 48°C for 2 min, and the
supernatant was collected as nuclear extracts.
Immunoblotting
Cell lysates were prepared in 100–200 μL of 1x sodium
dodecyl sulfate (SDS) lysis buffer [125 mM Tris–HCl
(pH 6.8), 4% SDS, 0.004% bromophenol blue, and 20%
glycerol]. Protein contents were measured using BCA
Protein Assay Reagent (Pierce, Rockford, IL, USA). Equal
amounts of proteins were loaded onto a 10% discon-
tinuous SDS/polyacrylamide gel and electrophoretically
transferred to PVDF membranes (Millipore Corporation,
Billerica, MA, USA) blocked with 5% non-fat dry milk in
phosphate-buffered saline-Tween-20 (0.1%, v/v) for 1 h.
The membranes were then incubated at 4°C overnight
with or without 2 h incubation at room temperature
with one of the following primary antibodies: anti-RelA
(1 : 1000, Santa Cruz Biotechnology), anti-phospho-Ser536-
RelA (pRelA; 1:1000; Cell Signaling Technology), anti-STAT3
(1:500, Santa Cruz Biotechnology), anti-phospho-Tyr705-
STAT3 (1:1000, Cell signaling Technology), anti-E-cadherin
(1:1000, BD Biosciences, San Jose, CA, USA), anti-Snail
(1:1000, Santa Cruz Biotechnology), anti-MMP9 (1:1000,
Neomarkers), anti-β-actin (1:1000, Sigma, St Louis, MO,USA) and anti-TFIIB (1:1,000, BD Bioscience). Horserad-
ish peroxidase-conjugated anti-rabbit IgG (1:2000, Zymed,
San Francisco, CA, USA) or anti-mouse IgG (1:2500,
Santa Cruz Biotechnology) was used as a secondary anti-
body. Enhanced chemiluminescence was used to detect
the immunoreactive proteins. Equal protein loading was
confirmed by β-actin (whole-lysate protein) or TFIIB
(nuclear protein).
Transient transfection and luciferase reporter assay
The NF-κB-luciferase reporter plasmid (pNF-κB-luciferase)
(Stratagene, La Jolla, CA, USA) contains a 5x NF-κB
response element fused to luciferase. The STAT-luciferase
reporter plasmid (pSTAT-luciferase) (Addgene plasmid
8688) contains four copies of the sequence GGTTCCCGT
AAATGCATCA (TTCCCGTAA is the STAT-binding site)
fused to luciferase. SNU-638 cells were transiently co-
transfected with 0.4 μg of luciferase reporter plasmid and
0.4 μg of β-galactosidase vector, an internal control, using
LipofectAMINE Plus (Life Technologies). Twenty-four hours
after transfection, assays for luciferase and β-galactosidase
were carried out using a Dual-Luciferase Reporter Assay
System (Promega, Madison, WI, USA). Luciferase activity
was measured on an AutoLumat LB 9505c luminometer
(Berthold Analytical Instruments, Nashua, Germany) and
was normalized by β-galactosidase activity. Luciferase ac-
tivity in control cells was arbitrarily set to 1.
Immunofluorescence staining
Cells were cultured on chamber slides. After 24 h, cells
were fixed with 4% paraformaldehyde, permeabilized with
0.5% Triton X-100 for 5 min, and blocked with 5% normal
donkey serum. After blocking, cells were incubated over-
night at 4°C with mixture of the following primary anti-
bodies: anti-pRelA (1:200; Cell Signaling Technology) and
anti-STAT3 (1:200, Santa Cruz Biotechnology). Alexa
fluor-555-conjugated anti-rabbit IgG (1:200, Life Technolo-
gies) and −488-conjugated anti-mouse IgG (1:200, Life
Technologies) were used as secondary antibodies. Cells
were stained with 40,6-diamidino-2-phenylindole (Life Tech-
nologies), which was used for nuclear staining. Immuno-
fluorescence was detected with a fluorescence microscope.
Wound-healing assay
Cells were cultured in 6-well plates until confluent. The
cell monolayer was scratched with a sterile pipette tip to
generate a wound. The remaining cells were washed
twice with culture medium to remove cell debris. Spon-
taneous cellular migration was monitored using a phase
contrast microscope and captured using an Olympus
Digital Camera (Olympus, Tokyo, Japan) at 0, 24 and
48 h. The area of the scratches was measured and quan-
tified using NIH Image Analysis software (version 1.62;
National Institute of Health, Bethesda, MD, USA).
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A 24-well Insert System using an 8 μm polyethylene ter-
ephthalate membrane was obtained (BD biosciences) and
coated with Matrigel (BD Biosciences). Inserts were rehy-
drated with RPMI1640 for 2 h at room temperature prior
to use. After rehydration, media was removed and cells
(1 × 105 cells/insert) were added to the top of each insert
chamber in RPMI1640 containing 1% FBS. Lower cham-
ber contained the medium with 10% FBS as a chemo-
attractant. After incubation for 48 h, non-invading cells
were carefully removed from the top of each insert with
a cotton swab. Invasive cells were stained with 0.2%
crystal violet in 20% methanol as described previously
[35] and were observed with an inverted microscope.
Stained cells also dissolved in 10% SDS, and absorbance
was measured at 570 nm using an ELISA reader (Bio-Rad,
Hercules, CA, USA).
Statistical analysis
For tissue array analysis, statistical analyses were con-
ducted using SPSS version 11.0 statistical software pro-
gram (SPSS, Chicago, IL, USA), and the chi-squared test
was used to determine the correlations between the
expressions of NF-κB, pSTAT3, and MMP9. For cell cul-
ture experiments, data were analyzed using GraphPad
Prism software for Windows Vista (version 4; GraphPad
Software, San Diego, CA, USA) and the two-tailed Stu-
dent’s t-test was used to determine the significances of
the results. P values of < 0.05 were considered statisti-
cally significant for all statistical analyses.
Results
NF-κB, pSTAT3 and MMP9 are positively correlated with
each other in clinical gastric cancer specimens
Representative results of the immunohistochemical stain-
ing are shown in Figure 1. Immunoreactivity for NF-κB
and pSTAT3 were found in both the nuclei and cytoplasm
of tumor cells. Cells showing distinct nuclear staining,
regardless of the presence of cytoplasmic staining, were
considered to express activated forms of NF-κB (Figure 1A)
or STAT3 (Figure 1B). On the other hand, the expressionRelA pSTAT3
A B
Figure 1 Representative immunohistochemical features of NF-κB, pST
RelA (p65)-positive. (B) pSTAT3-positive. (C) MMP9-positive. (D) Negative coof MMP9 was detected mainly in the cytoplasm of tumor
cells (Figure 1C). Positive immunoreactivity for nuclear
NF-κB was found in 41 of 255 (16%) of clinical samples
of gastric cancer. In addition, the expression of nuclear
pSTAT3 and cytoplasmic MMP9 were found in 61 of
255 (24%) and 46 of 255 (18%) of gastric cancer speci-
mens, respectively. Data concerning the correlations
between NF-κB activation, STAT3 activation, and MMP9
expression are summarized Table 1. NF-κB activation was
found to be significantly and positively correlated with
STAT3 activation (P = 0.038) and MMP9 expression (P =
0.001). Similarly, STAT3 activation was also correlated
with MMP9 expression (P = 0.022).
IκBαM overexpression reduces STAT3 expression and
activation
Since the relationship between NF-κB and STAT3 has
been dependent on the cellular context and cell type
[3,24-27], we performed in vitro experiments. To investi-
gate whether STAT3 is regulated by NF-κB, we produced
stable cell lines from SNU-638 and MKN1 cells overex-
pressing IκBαM. Immunoblotting analysis (Figure 2A)
was performed to determine the protein expression of
NF-κB p65 subunit phosphorylated at serine-536 (pRelA)
in addition to the protein expression of total NF-κB p65
(RelA), because an important site of phosphorylation of
NF-κB p65 subunit is at serine-536, and this phosphoryl-
ation is involved in regulation of transcriptional activity,
nuclear localization, and protein stability [36]. Our results
showed that NF-κB activation (manifested as pRelA ex-
pression) was down-regulated, whereas total RelA protein
expression was not modulated. Consistently, luciferase
reporter assay also showed that NF-κB transcriptional
activity markedly decreased in IκBαM-overexpressing
cells (Figure 2B). Then, we assessed whether NF-κB reg-
ulates the STAT3 activation by immunoblotting and
found that IκBαM overexpression decreased the STAT3
expression and activation (manifested as pSTAT3 ex-
pression) (Figure 2A and 2G). STAT luciferase reporter
assay also showed that STAT transcriptional activity was
decreased in IκBαM-overexpressing cells (Figure 2C). InMMP9
C D
Negative control
AT3 and MMP9 in human gastric cancer specimens. (A) NF-κB
ntrol treated without the primary antibodies. Scale bars = 100 μm.
Table 1 Correlation between expressions of NF-κB,
pSTAT3 and MMP9 in human gastric cancer specimens
NF-κB P
Positive (%) Negative (%)
Total 41 (16) 214 (84)
pSTAT3
Positive 15 (25) 46 (75) 0.038*
Negative 26 (13) 168 (87)
MMP9
Positive 15 (33) 31 (67) 0.001*
Negative 26 (12) 183 (88)
pSTAT3 P
Positive (%) Negative (%)
Total 61 (24) 194 (76)
MMP9
Positive 17 (37) 29 (63) 0.022*
Negative 44 (21) 165 (79)
NF-κB, nuclear factor-κB; pSTAT3, phospho-Tyr705-signal transducers and
activators of transcription 3; MMP9, matrix metalloproteinase 9.
* Considered to be statistically significant (< 0.05).
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that pRelA and STAT3 were colocalized in the nucleus
of the same gastric cancer cells, which was reduced in
IκBαM-overexpressing cells (Figure 2D).
Next, to investigate whether there is a crosstalk between
NF-κB and STAT3, STAT3 was silenced by transfection
of STAT3 siRNA. Immunoblotting showed that STAT3
silencing decreased STAT3 expression and activation,
but neither total RelA nor pRelA expression was changed
in STAT3-silenced cells (Figure 2E and 2H). In addition,
luciferase reporter assay confirmed that STAT3 silencing
did not modulate NF-κB transcriptional activity (Figure 2F).
Taken together, these findings suggest that STAT3 acts as
a downstream molecule of NF-κB in NF-κB pathway.
NF-κB suppression decreases the migration and invasion
through the regulation of EMT markers
In the initial steps of metastasis of carcinoma cells, epi-
thelial cancer cells change their phenotype to mesenchy-
mal phenotype and become motile and invasive by a
process called epithelial-mesenchymal transition (EMT)
[37]. This process includes down-regulation of epithelial
markers and up-regulation of mesenchymal markers [37].
To confirm the effect of NF-κB activation on gastric can-
cer cell motility, we used a stable SNU-638 and MKN1
cells overexpressing IκBαM. Wound-healing assay showed
that IκBαM overexpression significantly decreased migra-
tion of gastric cancer cells (by 51% in SNU-638 cells and
by 59% in MKN1 cells) compared with control cells
infected with an empty vector (Figure 3A and 3D). More-
over, invasion assay also showed that IκBαM overexpressiondecreased invasion of gastric cancer cells (by 28% in
SNU-638 cells and by 37% in MKN1 cells) compared
with control cells (Figure 3B and 3E).
To further examine the role of NF-κB in EMT of gastric
cancer cells, we analyzed the effect of NF-κB inhibition
on the expressions of representative EMT marker pro-
teins. Immunoblotting showed that the expression of
E-cadherin, a representative epithelial marker, increased,
whereas the expression of mesenchymal markers Snail and
MMP9 decreased after IκBαM overexpression (Figure 3C).
STAT3 silencing decreases the migration and invasion
through regulation of EMT markers
Next, we confirmed the effects of STAT3 silencing on
the motility and invasiveness in gastric cancer cells. As
expected from the previous report [21], STAT3 silencing
suppressed cell migration (by 49% in SNU-638 cells and
by 57% in MKN1 cells) compared with control siRNA-
transfected gastric cancer cells (Figure 4A and 4D).
Moreover, STAT3 silencing also decreased invasiveness
(by 27% in SNU-638 cells and by 30% in MKN1 cells)
compared with control cells (Figure 4B and 4E). We
found that E-cadherin increased, whereas Snail and MMP9
decreased after transfection of STAT3 siRNA (Figure 4C).
NF-κB and STAT3 cooperatively induce migration and
invasion of gastric cancer cells
Our results in the present study showed that NF-κB and
STAT3 played important roles in migration and invasion,
and that NF-κB was an upstream regulator of STAT3. To
examine the combined effect of NF-κB and STAT3 on
the metastatic potential of gastric cancer cells, we per-
formed co-transfection of IκBαM and STAT3 siRNA into
SNU-638 cells.
To confirm the effects of co-transfection of IκBαM
and STAT3 siRNA on expression of pRelA and pSTAT3,
we obtained whole cell lysates and nuclear extracts and
performed immunoblotting. We found that double knock-
down of RelA and STAT3 induced marked down-regulation
of pSTAT3 expression in both the whole cell lysates
(1st–3rd rows in Figure 5A) and nuclear extracts (4th–
6th rows in Figure 5A).
In quantitative terms, the migration capacity decreased
by 50% in IκBαM-overexpressing cells, and by 45% in
STAT3-slienced cells compared with control cells. In the
co-transfected cells, the migration capacity was remark-
ably inhibited when STAT3 was further silenced (81%
lower than that of the control) (Figure 5B). Similarly,
invasion assay showed that cells with down-regulation
of both NF-κB and STAT3 showed lower invasion abil-
ity (56% lower than that of the control) than those with
down-regulation of either alone (Figure 5C). These data
suggest that STAT3 in this system is induced not only

























































































Figure 2 Effect of downregulation of NF-κB p65 on the STAT3 activation in gastric cancer cells and vice versa. (A-D) SNU-638 cells were
infected with either MFG.IκBαM.IRES.puro (IκBαM) retroviral vector or empty (EGFP) vector. (A) The protein expressions of total NF-κB p65 (RelA),
phospho-Ser536-NF-κB p65 (pRelA), total STAT3 and phosphor-Tyr705-STAT3 (pSTAT3) were determined by immunoblotting. (B) Cells were
transiently co-transfected with pNF-κB-luciferase and a β-galactosidase vector, and effect of IκBαM overexpression on NF-κB transcriptional activity
was determined by luciferase reporter assay. Each bar represents the mean ± SD (n = 6). * P < 0.05 versus control cells infected with an empty
vector. (C) Cells were transiently co-transfected with pSTAT-luciferase and a β-galactosidase vector, and effect of IκBαM overexpression on STAT
transcriptional activity was determined by luciferase reporter assay. Each bar represents the mean ± SD (n = 5). * P < 0.05 versus control cells
infected with an empty vector. (D) 4’,6’-Diamidino-2-phenylindole staining (blue) and double immunofluorescence staining showing the nuclear
colocalization of pRelA (red) and STAT3 (green). (E and F) SNU-638 cells were transiently transfected with control siRNA (siCtrl) or STAT3 siRNA
(siSTAT3). (E) The effects of STAT3 silencing on the protein expressions of total STAT3, pSTAT3, total RelA and pRelA were determined by
immunoblotting. (F) Luciferase reporter assay was performed to show the regulation of NF-κB activation by STAT3 after STAT3 silening. Each bar
represents the mean ± SD (n = 6). * P < 0.05 versus control siRNA-transfected cells. (G) Immunoblotting for pRelA and pSTAT3 in MKN1 cells after
IκBαM overexpression. (H) Immunoblotting for total STAT3 and pSTAT3 in MKN1 cells after STAT3 silencing.
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Figure 3 Effect of IκBαM overexpression on metastatic potential of gastric cancer cells. SNU-638 (A-C) cells and MKN1(D and E) cells were
infected with either IκBαM retroviral vector or an empty (EGFP) vector. (A and D) Confluent cell monolayers were wounded and cell migration
was analyzed by wound-healing assay 48 h after scratching. (B and E) Cells were seeded in the upper chamber coated with Matrigel and invasion
ability was measured 48 h after cell plating. Results were calculated as percentages relative to control cells infected with an empty vector. Each
bar represents the mean ± SD (n = 4). * P < 0.05 versus control cells infected with an empty vector. (C) The protein expressions of E-cadherin,
Snail, MMP9 and β-actin expressions were determined by immunoblotting.
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NF-κB independent pathways including some cytokines
[38] and tyrosine kinases [39]. We also found that E-
cadherin expression was increased whereas Snail ex-
pression was decreased in cells with down-regulation of
both NF-κB and STAT3 compared with those with down-
regulation of either alone (Figure 5D).
Discussion
Understanding of a clear regulatory path of signaling
molecules in cancer cells is a pre-requisition to successful
co-development of therapeutic targets for tumors. Since
the pivotal role of NF-ĸB in gastric cancer progression has
been shown [16,18], a thorough understanding of NF-ĸBpathway can lead to future studies and drug development
which could provide a novel option in the treatment
of this disease. Although both NF-κB and STAT3 are
shown to be involved in the metastasis of gastric can-
cer [16,18,21], the link between NF-ĸB and STAT3 has
not been validated. In the present study, we investi-
gated the relationship between NF-κB and STAT3 in
terms of gastric cancer metastasis. To the best of our
knowledge, this is the first study to show the associ-
ation between NF-κB and STAT3 in gastric cancer.
In the present study, constitutive activation of NF-κB
and STAT3 was found in 16% and 24% of 255 gastric
cancer specimens, respectively, and they showed a positive
correlation (P = 0.038). In addition, our in vitro experiments







































































































Figure 4 Effect of STAT3 silencing on metastatic potential of gastric cancer cells. SNU-638 cells (A-C) and MKN1 cells (D and E) were
transiently transfected with control siRNA (siCtrl) or STAT3 siRNA (siSTAT3). (A and D) Cell migration capacity was evaluated by wound-healing
assay 48 h after scratching. (B and E) Cell invasion ability was measured 48 h after cell plating. Results were calculated as percentages relative to
control siRNA-transfected cells. * P < 0.05 versus control cells (n = 4). (C) The protein expressions of E-cadherin, Snail, MMP9 and β-actin in SNU-
638 cells were determined by immunoblotting after STAT3 silencing.
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sion of total STAT3 and pSTAT3, which was possibly
caused by the suppression of STAT3 at the transcriptional
or translational level. Since we wondered whether there is a
reciprocal regulatory loop between NF-κB and STAT3, we
further analyzed the effect of STAT3 silencing on the
NF-κB activation. However, we found that STAT3 did
not affect either NF-κB expression or activation. Thus,
these results suggest that STAT3 is a downstream mol-
ecule of NF-κB in NF-κB pathway. Our observations
contrast with a report by Yang et al. (2007), which
showed that STAT3 and RelA can heterodimerize to
transcriptionally regulate NF-κB-dependent genes [40].Although Wani et al. (2011) reported that NF-κB activa-
tion induced STAT3 activation mediated by IL-6 [26],
the present study did not show whether IL-6 is reduced
in the SNU-638 cells overexpressing IκBαM, which
may account for the reduced STAT3 levels. Thus, fur-
ther investigations are needed to obtain a better under-
standing of the mechanism involved in NF-κB-induced
STAT3 activation.
EMT confers acquisition of cell migration and invasion
as well as molecular alterations in cancer cells [37]. Al-
though the existence of EMT has not been shown in all
types of cancers, previous studies have demonstrated
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Figure 5 Synergistic effect of NF-κB and STAT3 on metastatic potential of gastric cancer cells. Stable SNU-638 cells infected with either
IκBαM retroviral vector or an empty (EGFP) vector were transiently co-transfected with either control siRNA (siCtrl) or STAT3 siRNA (siSTAT3).
(A) Whole cell lysates (WL) and nuclear extracts (NE) were obtained 24 h after co-transfection and protein levels for pRelA, pSTAT3 and β-actin
or TFIIB were measured by immunoblotting. (B) Effect of interaction of NF-κB and STAT3 on cell migration capacity was evaluated by wound-healing
assay 48 h after scratching. (C) Effect of interaction of NF-κB and STAT3 on cell invasion ability was measured by invasion assay 48 h after cell plating.
Results were calculated as percentages relative to controls. Each bar represents the mean ± SD (n = 4). * P < 0.05 and ** P < 0.005. (D) The protein
expressions of E-cadherin, Snail and β-actin in SNU-638 cells were determined by immunoblotting after co-transfection of IκBαM and siSTAT3.
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topic xenograft tumors and surgical gastric cancer speci-
mens [41-43]. In the present study, we showed that
IκBαM overexpression decreased the migration and in-
vasion of gastric cancer cells. Moreover, IκBαM overepx-
ression increased E-cadherin expression and decreased
Snail expression, which indicates the change toward the
mesenchymal phenotype. Thus, these results indicate
that NF-κB might contribute to malignant progression
through promotion of EMT.
Regarding the role of STAT3 in gastric cancer cells,
Okamoto et al. (2011) found that STAT3 activation induced
cancer cell motility through the Janus kinase pathway,
whereas it enhanced survival of MET-activated gastric
cancer cells [21]. Thus, they concluded that STAT3 plays
differential roles depending on the upstream regulator of
STAT3 activation in gastric cancer cells. In the present
study, STAT3 silencing decreased the migration and inva-
sion in SNU-638 gastric cancer cells with high NF-κBactivity [44]. These findings, thus, suggest that STAT3 ac-
tivation through NF-κB could contribute to the metastatic
potential of a subset of gastric cancer cells.
MMP9 plays a critical role in maintaining the degrad-
ation and synthesis of extracellular matrix, and was shown
to be positively associated with gastric cancer cell metasta-
sis in animal models [45] and human gastric cancers [46].
Here, we examined the MMP9 expression and found
that both NF-κB and STAT3 activation were positively
correlated with MMP9 expression in clinical gastric cancer
samples and in cultured cells. However, Table 1 showed
that there are much more MMP9-positive cells (18%) than
cells with activation of both NF-κB and STAT3 (6%).
Therefore, we speculate that MMP9 can be induced by
many other pathways independent on NF-κB/STAT3 sig-
naling pathway in gastric cancer [47,48].
Although targeted therapies may offer enhanced effi-
cacy and improved selectivity (and therefore less tox-
icity), mostly their effects are not durable when they are
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http://www.biomedcentral.com/1471-230X/13/29used alone. For this reason, combination therapies are
often needed to effectively treat many tumors [49]. In
the present study, we found that the combination of
NF-κB inhibition and STAT3 silencing further reduced
migration and invasion of gastric cancer cells compared
to down-regulation of each molecule. Therefore, NF-κB
and STAT3 seems to act in a synergistic manner in
modulating migration and invasion of gastric cancer cells.
Conclusions
Our results suggest that NF-κB and its downstream mol-
ecule STAT3 synergistically promote the metastatic poten-
tial of gastric cancer cells. Thus, the targeted combination
therapy using NF-κB and STAT3 inhibitors appears to be
a good approach to combat gastric cancer metastasis.
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